Latest Breaking News On - Benevolent platform - Page 4 : comparemela.com

The Galien Foundation Announces 2023 Prix Galien UK Award Candidates for Best Biotechnology Product, Best Digital Health Solution, Best Medical Technology, Best Pharmaceutical Product and Newly Added, Best Public Sector Innovation

Winners to be Announced and Recognised on 11 May at the Prix Galien UK Awards Ceremony in London LONDON, May 2, 2023 /PRNewswire/ The Galien Foundation, the premier global institution

City ofUnited kingdomKara bradleySanofi xenpozymePrix galienDame juneRoland mehlMark walportDavid weatherallDigital health solution candidatesTechnology candidatesWorld health organization department of digitalNatural history museumDeciphera pharmaceuticals netherlandsKing college londonDocobo ltd

BenevolentAI Announces Top-Line Phase IIa Results for Its Topical pan-Trk Inhibitor BEN-2293 (1%) in Mild-to-Moderate Atopic Dermatitis

Successfully met primary endpoint with BEN-2293 found to be safe and well tolerated Secondary efficacy endpoints, to reduce itch and inflammation, were not achieved. However, initial analyses in. | April 5, 2023

City ofUnited kingdomNew yorkUnited statesAnne phelanCompany euronext amsterdamRegulatory newsMarket abuse regulationEuronext amsterdamEczema areaSeverity indexNumerical rating scaleChief scientific officerBenevolent platformBenevolentai stock exchangePress release

BenevolentAI : Inside Information / Ad Hoc Information Press Release for 2023 Convening Notice of Annual General Meeting

BenevolentAI announces publication of convening notice for AGM London, UK, 24 March 2023: BenevolentAI , a leading, clinical-stageAI-enabled drug discovery and. | March 24, 2023

City ofUnited kingdomNew yorkUnited statesJudit molnarWinston churchillFleur woodCompany euronext amsterdamDeputy companyEuronext amsterdamAnnual general meetingAnnual reportCompany secretaryBenevolent platformBenevolentai stock exchangePress release

BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2022

A year of strong operational progress with focused investment to drive future growth Regulatory News: BenevolentAI ("BenevolentAI" or the "Company" or the "Group") (Euronext Amsterdam: BAI), a

United statesUnited kingdomCity ofGrand duchy of luxembourgDennis riedlKenneth mulvanyNick keherJoanna shieldsJohn orloffJean rabyEli lillyMichael brennanOliver brandicourtBen atwell simon conwayNicholas keherSusan liautaud

BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor, as a first-in-class treatment for ulcerative colitis

BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor, as a first-in-class treatment for ulcerative colitis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesUnited kingdomCity ofFoster mitchellRajin kangBen atwellAnne phelanSimon conwayFleur woodVp communicationsHealthcare products regulatory agencyWall streetBenevolent platformEuronext amsterdamClinical trial application